PLoS ONE (Jan 2023)

Presence and activity of Fibrinogen like protein 2 in platelets.

  • Izhack Cherny,
  • Pinhas Hasin,
  • Lital Kalich Philosoph,
  • Yael Shahal-Zimra,
  • Ronit Gurion,
  • Esther Rabizadeh

DOI
https://doi.org/10.1371/journal.pone.0285735
Journal volume & issue
Vol. 18, no. 5
p. e0285735

Abstract

Read online

BackgroundFibrinogen-like protein 2 (FGL2) is a serine protease capable of converting prothrombin into thrombin (i.e., prothrombinase-like activity) while bypassing the classic coagulation cascade. It has been reported to be expressed by mononuclear blood cells and endothelial cells. There are multiple reports that FGL2 supports tumor development and metastasis. However, in the blood, the origin and functional significance of FGL2 has not been established.ObjectiveTo determine if FGL2, a malignancy related enzyme, is present in platelets.MethodsPeripheral blood samples were collected in K2 EDTA tubes. Blood cells and platelets were separated and thoroughly washed to produce plasma-free samples. Procoagulant activity was measured in the cell lysates using a thrombin generation test or an adjusted prothrombin time (PT) test in plasma deficient of factor X. The findings were further supported by confocal microscopy, immunoprecipitation, flow cytometry, enzyme-linked immunosorbent assays and specific inhibition assays.ResultsFGL2 protein was readily detected in platelets. Also, despite being expressed by lymphocytes, FGL2 prothrombinase-like activity was solely detected in platelet samples, but not in white blood cell samples. Quiescent platelets were shown to contain the FGL2 protein in an active form. Upon activation, platelets secreted the active FGL2 into the milieu.ConclusionsActive FGL2 is found in platelets. This suggests another role for the involvement of platelets in malignancies.